The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Cap 1 Messenger RNA Synthesis with Co‐transcriptional CleanCap ® Analog by In Vitro Transcription
Open accessAbstract
Synthetic messenger RNA (mRNA)−based therapeutics are an increasingly popular approach to gene and cell therapies, genome engineering, enzyme replacement therapy, and now, during the global SARS‐CoV‐2 pandemic, vaccine development. mRNA for such purposes can be synthesized through an enzymatic in vitro transcription (IVT) reaction and formulated for in vivo delivery. Mature mRNA requires a 5′‐cap for gene expression and mRNA stability. There are two methods to add a cap in vitro: via a two‐step multi‐enzymatic reaction or co‐transcriptionally. Co‐transcriptional methods minimize reaction steps and enzymes needed to make mRNA when compared to enzymatic capping. CleanCap ® AG co‐transcriptional capping results in 5 mg/ml of IVT with 94% 5′‐cap 1 structure. This is highly efficient compared to first‐generation cap analogs, such as mCap and ARCA, that incorporate cap 0 structures at lower efficiency and reaction yield. This article describes co‐transcriptional capping using TriLink Biotechnology's CleanCap ® AG in IVT. © 2021 The Authors. This article was corrected on 22 November 2021 and 26 July 2022 . See the end of the full text for details. Basic Protocol 1 : IVT with CleanCap Basic Protocol 2 : mRNA purification and analysis
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The current new generation of cap analogs is the CleanCap® cap analogs developed by TriLink BioTechnologies (San Diego, CA, USA),126 which can be co-transcribed with the target mRNA to obtain the cap1 structure, thus solving the issues of low efficiency and high enzyme costs of traditional capping methods.”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [126]
In the citing paper
“The use of CleanCap® cap analogs reduces the probability of reverse capped, uncapped, and cap0 intermediates, and the co-transcribed mRNA only possesses a cap1 structure, therefore capping rate can be 90% or higher.52,126”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [126]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aviv, H., & Leder, P. (1972) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.69.6.1408 · Cited by 6,636
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y.-H., Li, H., Lau, F., Ebina, W., Mandal, P. K., Smith, Z. D., Meissner, A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.08.012 · Cited by 2,662
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
SARS-CoV-2 vaccines in development
Krammer, F. (2020) · Nature · doi:10.1038/s41586-020-2798-3 · Cited by 2,098
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
mRNA capping: biological functions and applications
Ramanathan, A., Robb, G. B., & Chan, S. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw551 · Cited by 961
Karikó, K., Muramatsu, H., Ludwig, J., & Weissman, D. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr695 · Cited by 898
A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA
Baiersdörfer, M., Boros, G., Muramatsu, H., Mahiny, A., Vlatkovic, I., Sahin, U., & Karikó, K. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.02.018 · Cited by 569
Conventional and unconventional mechanisms for capping viral mRNA
Decroly, É., Ferrón, F., Lescar, J., & Canard, B. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2675 · Cited by 495
Cap and cap‐binding proteins in the control of gene expression
Topisirović, I., Svitkin, Y. V., Sonenberg, N., & Shatkin, A. J. (2010) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.52 · Cited by 413
(2001) · PubMed Central · Cited by 342
Discovery of m7G-cap in eukaryotic mRNAs
Furuichi, Y. (2015) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.91.394 · Cited by 267
Vaidyanathan, S., Azizian, K. T., Haque, A. K. M. A., Henderson, J. M., Hendel, A., Shore, S., Antony, J. S., Hogrefe, R. I., Kormann, M. S. D., Porteus, M. H., et al. (2018) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2018.06.010 · Cited by 262 · cited 2×
“Sequence optimization of the ORF using bioinformatic software may improve therapeutic applications (Vaidyanathan et al., 2018).”
BackgroundMethodSelf-citationCharacterization of T7-specific Ribonucleic Acid Polymerase
Chamberlin, M. J., & Ring, J. (1973) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)44211-7 · Cited by 222
Quantifying the RNA cap epitranscriptome reveals novel caps in cellular and viral RNA
Wang, J., Chew, B. L. A., Lai, Y., Dong, H., Xu, L., Balamkundu, S., Cai, W. M., Cui, L., Liu, C., Fu, X.-Y., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz751 · Cited by 201
2′-O-ribose methylation of cap2 in human: function and evolution in a horizontally mobile family
Werner, M., Purta, E., Kaminska, K. H., Cymerman, I. A., Campbell, D. A., Mittra, B., Zamudio, J. R., Sturm, N. R., Jaworski, J., & Bujnicki, J. M. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr038 · Cited by 174
Ensinger, M. J., Martin, S. A., Paoletti, E., & Moss, B. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.7.2525 · Cited by 167
Determinants and implications of mRNA poly(A) tail size – Does this protein make my tail look big?
Jalkanen, A. L., Coleman, S. J., & Wilusz, J. (2014) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2014.05.018 · Cited by 154
Sikorski, P. J., Warminski, M., Kubacka, D., Ratajczak, T., Nowis, D., Kowalska, J., & Jemielity, J. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa032 · Cited by 142
A simple procedure for gel electrophoresis and Northern blotting of RNA
Goda, S. K., & Minton, N. P. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.16.3357 · Cited by 121
Rapid development and deployment of high‐volume vaccines for pandemic response
Kis, Z., Kontoravdi, C., Dey, A. K., Shattock, R., & Shah, N. (2020) · Journal of Advanced Manufacturing and Processing · doi:10.1002/amp2.10060 · Cited by 105
Formation of the guanylylated and methylated 5′-terminus of vaccinia virus mRNA
Moss, B., Gershowitz, A., Wei, C.-M., & Boone, R. F. (1976) · Virology · doi:10.1016/0042-6822(76)90163-x · Cited by 95
RNA analysis by ion-pair reversed-phase high performance liquid chromatography
Azarani, A. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.2.e7 · Cited by 94
RNA Purification – Precipitation Methods
Walker, S. E., & Lorsch, J. R. (2013) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-420037-1.00019-1 · Cited by 92
A New Vaccine to Battle Covid-19
Haynes, B. F. (2020) · New England Journal of Medicine · doi:10.1056/nejme2035557 · Cited by 71
Righetti, P. G., & Verzola, B. (2001) · Electrophoresis · doi:10.1002/1522-2683(200107)22:12 · Cited by 60
Use of DNAzymes for site-specific analysis of ribonucleotide modifications
Hengesbach, M., Meusburger, M., Lyko, F., & Helm, M. (2007) · RNA · doi:10.1261/rna.742708 · Cited by 60
Galloway, A., Atrih, A., Grzela, R., Darżynkiewicz, E., Ferguson, M. A. J., & Cowling, V. H. (2020) · Open Biology · doi:10.1098/rsob.190306 · Cited by 56
Optimizing Modified mRNA In Vitro Synthesis Protocol for Heart Gene Therapy
Hadas, Y., Sultana, N., Youssef, E., Sharkar, M. T. K., Kaur, K., Chepurko, E., & Zangi, L. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.07.006 · Cited by 41
Ishikawa, M., Murai, R., Hagiwara, H., Hoshino, T., & Suyama, K. (2009) · Nucleic Acids Symposium Series · doi:10.1093/nass/nrp065 · Cited by 35
Quantitation of Nucleic Acids and Proteins
Gallagher, S. R., & Desjardins, P. R. (2011) · Current Protocols Essential Laboratory Techniques · doi:10.1002/9780470089941.et0202s5 · Cited by 17
Detection of the 5'-cap structure of messenger RNAs with the use of the cap-jumping approach
Efimov, V. A. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.22.4751 · Cited by 17
Denaturation and Electrophoresis of RNA with GlyoxalPreprint
Rio, D. C. (2015) · Cold Spring Harbor Protocols · doi:10.1101/pdb.prot081000 · Cited by 17
Armstrong, J. A., & Schulz, J. R. (2008) · Current Protocols Essential Laboratory Techniques · doi:10.1002/9780470089941.et0702s00 · Cited by 14
Purification and Concentration of Nucleic Acids
Dowhan, D. H. (2012) · Current Protocols Essential Laboratory Techniques · doi:10.1002/9780470089941.et0502s06 · Cited by 12
Fujii, S., Inagaki, K., Miyashita, S., Groombridge, A. S., Nagasawa, K., Chiba, K., & Takatsu, A. (2013) · Electrophoresis · doi:10.1002/elps.201300477 · Cited by 11
Flagged first, then by citations
Research works printed but not linked: 1
- Green M. R., 2019, Isolation of poly(A)+ messenger RNA using magnetic oligo(dT) beads, Cold Spring Harbor Protocols, 2019
Cited by
Sorted by citations
Advances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601
Unlocking the promise of mRNA therapeutics
Rohner, E., Yang, R., Foo, K. S., Goedel, A., & Chien, K. R. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01491-z · Cited by 612
Innate immune mechanisms of mRNA vaccines
Verbeke, R., Hogan, M. J., Loré, K., & Pardi, N. (2022) · Immunity · doi:10.1016/j.immuni.2022.10.014 · Cited by 535
Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines
Nance, K. D., & Meier, J. L. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00197 · Cited by 466
Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability
Zhang, L., More, K. R., Ojha, A., Jackson, C. B., Quinlan, B. D., Li, H., He, W., Farzan, M., Pardi, N., & Choe, H. (2023) · npj Vaccines · doi:10.1038/s41541-023-00751-6 · Cited by 244
Metadata
- Authors
- Henderson, J. M., Ujita, A., Hill, E., Yousif‐Rosales, S., Smith, C., Ko, N., McReynolds, T., Cabral, C. R., Escamilla‐Powers, J. R., & Houston, M. E.
- Affiliations
- TriLink BioTechnologies (United States) (US)
- Corresponding author
- Henderson, Jordana M.
- Venue
- Current Protocols
- Publisher
- Wiley
- Published
- 2021-02
- Volume
- 1
- Issue
- 2
- Pages
- e39-e39
- ISSN
- 2691-1299 (ISSN-L)
- OpenAlex
- W3127832258
- Cited by
- 231
- References
- 38
- Citations by year
- 2026: 39 · 2025: 53 · 2024: 49 · 2023: 45 · 2022: 36 · 2021: 9
- FWCI
- 10.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Current Protocols (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Molecular Biology Techniques and Applications
- Keywords
- mRNA therapeutics, in vitro transcription, mRNA synthesis, mRNA purification, mRNA stability, mRNA vaccines, SARS-CoV-2
- MeSH terms
- Humans, RNA Cap Analogs, RNA, Messenger, Protein Biosynthesis, RNA Stability, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
